Neuropore: UCB Initiates Phase 1b USBased Multicenter Clinical Trial in Parkinsons Disease Patients with UCB0599 a Compound Arising from the NeuroporeUCB Collaboration

Neuropore Therapies Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinsons disease patients with UCB0599 in the United States of America. UCB0599 an alphasynuclein misfolding inhibitor is a ...